Related Experiment Video

Updated: Aug 18, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

New approaches in advanced renal cell carcinoma

Brian I Rini1

  • 1Department of Medicine, UCSF Comprehensive Cancer Center, San Francisco, CA, USA. brini@medicine.ucsf.edu

Urologic Oncology
|May 12, 2005
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Experiment Videos

Last Updated: Aug 18, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

European urology·2026

Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

The oncologist·2026

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Nature reviews. Clinical oncology·2026

Evaluation, etiology, and management of gross hematuria following radical cystectomy and orthotopic neobladder.

Urologic oncology·2026

Technical requirements and platform considerations for molecular residual disease in genitourinary tumors.

Urologic oncology·2026

Optimal prostate-specific antigen thresholds for early salvage therapy after robotic-assisted radical prostatectomy.

Urologic oncology·2026

Reassessing the role of segmental ureterectomy in upper tract urothelial carcinoma: Functional durability and propensity-matched oncological outcomes.

Urologic oncology·2026

Intravesical recurrence is associated with increased Treg and exhausted CD8+ T cells in upper tract urothelial carcinoma.

Urologic oncology·2026

Defining a hilar "danger zone" to guide surgical decision-making in T1 renal cell carcinoma.

Urologic oncology·2026

Overcoming Resistance to Immune Checkpoint Blockade: Mechanistic Insights and Emerging Therapeutic Directions.

Iranian journal of immunology : IJI·2026

Cooperative Suppression of Ovarian Cancer Growth by 1,25-Dihydroxyvitamin D3 and Sodium Selenite Mediated Through SEPP1 Induction.

Cancer medicine·2026

The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review.

Cancer medicine·2026

Steven-Johnson Syndrome and Toxic Epidermal Necrolysis in a Patient Treated With Cabozantinib: A Case Report of a Fatal Adverse Reaction.

Asia-Pacific journal of clinical oncology·2026

Durable response to olaparib plus continued PD-1 blockade in germline PALB2-mutated triple-negative breast cancer with leptomeningeal metastasis: A case report.

Medicine·2026

Delineating SWI/SNF gene and subtype expression in cancer.

Epigenetics & chromatin·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us